GALT News and Press, Galectin Therapeutics Inc. From 08/14/23

2023-08-14 09:29:20 ET Galectin Therapeutics press release ( NASDAQ: GALT ): Q2 GAAP EPS of -$0.15. Cash and cash equivalents of $17.97m For further details see: Galectin Therapeutics GAAP EPS of -$0.15

NORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023. These results are include...

2023-05-27 04:01:42 ET Summary Since February, there were multiple significant share price fluctuations with no news. Patient enrollment completed for a mid-stage clinical trial. The readout for this study was delayed. Galectin Therapeutics ( GALT ), is the micro...

2023-05-15 09:25:33 ET Galectin Therapeutics press release ( NASDAQ: GALT ): Q1 GAAP EPS of -$0.19. As of March 31, 2023, the Company had $17.8 million of cash and cash equivalents. Additionally, the Company has $40 million remaining available under a $60 mi...

NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023. These results are include...

NORCROSS, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Investment Conference on Tuesday, May 2, 2023. ...

NORCROSS, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic Conference on NASH Cirrhosis: From Mechanisms to Management , sponsored by the American Assoc...

2023-03-30 08:20:04 ET Galectin Therapeutics press release ( NASDAQ: GALT ): FY GAAP EPS of -$0.65 in-line. As of December 31, 2022, the Company had $18.6 million of cash and cash equivalents. Additionally, the Company has $50 million remaining available und...

NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022. These results are included i...

2023-03-16 09:09:42 ET Galectin Therapeutics ( NASDAQ: GALT ) said a data and safety monitoring board (DSMB) gave greenlight to continue a phase 2b/3 trial of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). The DSMB dec...